Adipose cell-adrenal interactions: current knowledge and future perspectives

Trends in Endocrinology and Metabolism

Volumn 19, Issue 3, 2008, Pages 100-103

  Ronconi, Vanessa ^a   Turchi, Federica ^a   Bujalska, Iwona J ^b   Giacchetti, Gilberta ^a   Boscaro, Marco ^a  

^a UNIVERSITÀ POLITECNICA DELLE MARCHE   (Italy)

^b UNIVERSITY OF BIRMINGHAM   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ADIPOCYTOKINE; ALDOSTERONE; ANGIOTENSIN II; ANGIOTENSIN RECEPTOR ANTAGONIST; BETA CATENIN; CANDESARTAN; DIPEPTIDYL CARBOXYPEPTIDASE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; MINERALOCORTICOID RECEPTOR;

ADIPOGENESIS; ADIPOSE TISSUE CELL; ADRENAL GLAND; CELL DIFFERENTIATION; CLINICAL TRIAL; CYTOKINE RELEASE; DRUG EFFECT; DRUG INHIBITION; HORMONE SYNTHESIS; HUMAN; INSULIN SENSITIVITY; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; OBESITY; PRIORITY JOURNAL; PROTEIN EXPRESSION; RADIOIMMUNOASSAY; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; REVIEW;

ADIPOSE TISSUE; ADRENAL GLANDS; CELL COMMUNICATION; HUMANS; HYPERTENSION; INSULIN RESISTANCE; MINERALOCORTICOIDS; RENIN-ANGIOTENSIN SYSTEM;

EID: 41149133025     PISSN: 10432760     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.tem.2008.01.004     Document Type: Review

References (47)

1. Arner P. The adipocytes in insulin resistance: key molecules and the impact of the thiazolidinediones. Trends Endocrinol. Metab. 14 (2003) 137-145
2. Kershaw E.E., and Flier J.S. Adipose tissue as an endocrine organ. J. Clin. Endocrinol. Metab. 89 (2004) 2548-2556
3. Pasquali R., et al. The hypothalamic-pituitary-adrenal axis activity in obesity and the metabolic syndrome. Ann. N. Y. Acad. Sci. 1083 (2006) 111-128
4. Bloem L.J., et al. The serum angiotensinogen concentration and variants of the angiotensinogen gene in white and black children. J. Clin. Invest. 95 (1995) 948-953
5. Cooper R., et al. ACE, angiotensinogen and obesity: a potential pathway leading to hypertension. J. Hum. Hypertens. 11 (1997) 107-111
6. Messerli F.H., et al. Obesity and essential hypertension. Hemodynamics, intravascular volume, sodium excretion, and plasma renin activity. Arch. Intern. Med. 141 (1981) 81-85
7. Massiera F., et al. Adipose angiotensinogen is involved in adipose tissue growth and blood pressure regulation. FASEB J. 15 (2001) 2727-2729
8. Faloia E., et al. Comparison of circulating and local adipose tissue renin-angiotensin system in normotensive and hypertensive obese subjects. J. Endocrinol. Invest. 25 (2002) 309-314
9. Giacchetti G., et al. Overexpression of the renin-angiotensin system in human visceral adipose tissue in normal and overweight subjects. Am. J. Hypertens. 15 (2002) 381-388
10. Janke J., et al. Mature adipocytes inhibit in vitro differentiation of human preadipocytes via angiotensin type 1 receptors. Diabetes 51 (2002) 1699-1707
11. Hauner H., et al. Promoting effects of glucocorticoids on the differentiation of human adipocyte precursor cells cultured in a chemically defined medium. J. Clin. Invest. 84 (1989) 1663-1670
12. Rondinone C.M., et al. Aldosterone stimulates differentiation of mouse 3T3-L1 cells into adipocytes. Endocrinology 132 (1993) 2421-2426
13. Zennaro M.C., et al. Hibernoma development in transgenic mice identifies brown adipose tissue as a novel target of aldosterone action. J. Clin. Invest. 101 (1998) 1254-1260
14. Fu M., et al. A nuclear receptor atlas: 3T3-L1 adipogenesis. Mol. Endocrinol. 19 (2005) 2437-2450
15. Caprio M., et al. Pivotal role of the mineralocorticoid receptor in corticosteroid-induced adipogenesis. FASEB J. 21 (2007) 2185-2194
16. Townsend R.R. Angiotensin and insulin resistance: conspiracy theory. Curr. Hypertens. Rep. 5 (2003) 110-116
17. Shiuchi T., et al. Angiotensin II type-1 receptor blocker valsartan enhances insulin sensitivity in skeletal muscles of diabetic mice. Hypertension 43 (2004) 1003-1010
18. Sharma A.M., et al. Angiotensin blockade prevents type 2 diabetes by formation of fat cells. Hypertension 40 (2002) 609-611
19. Furuhashi M., et al. Blockade of the renin-angiotensin system decreases adipocyte size with improvement in insulin sensitivity. J. Hypertens. 22 (2004) 1977-1982
20. Mori Y., et al. Angiotensin II receptor blockers downsize adipocytes in spontaneously type 2 diabetic rats with visceral fat obesity. Am. J. Hypertens. 20 (2007) 431-436
21. Zorad S., et al. Long-term angiotensin II AT1 receptor inhibition produces adipose tissue hypotrophy accompanied by increased expression of adiponectin and PPARγ. Eur. J. Pharmacol. 552 (2006) 112-122
22. Jandeleit-Dahm K.A.M., et al. Why blockade of the renin-angiotensin system reduces the incidence of new-onset diabetes. J. Hypertens. 23 (2005) 463-473
23. Licata G., et al. Central obesity and hypertension: relationship between fasting serum insulin, plasma renin activity, and diastolic blood pressure in young obese subjects. Am. J. Hypertens. 7 (1994) 314-320
24. Egan B.M., et al. Renin and aldosterone are higher and the hyperinsulinemic effect of salt restriction greater in subjects with risk factors clustering. Am. J. Hypertens. 7 (1994) 886-893
25. El Gharbawy A.H., et al. Arterial pressure, left ventricular mass, and aldosterone in essential hypertension. Hypertension 37 (2001) 845-850
26. Goodfriend T.L., et al. Visceral obesity and insulin resistance are associated with plasma aldosterone levels in women. Obes. Res. 7 (1999) 355-362
27. Engeli S., et al. Weight loss and the renin-angiotensin-aldosterone system. Hypertension 45 (2005) 356-362
28. Harp J.B., et al. Dietary weight loss decreases serum angiotensin-converting enzyme activity in obese adults. Obes. Res. 10 (2002) 985-990
29. Tuck M.L., et al. The effect of weight reduction on blood pressure, plasma renin activity, and plasma aldosterone levels in obese patients. N. Engl. J. Med. 304 (1981) 930-933
30. Ehrhart-Bornstein M., et al. Human adipocytes secrete mineralocorticoid-releasing factors. Proc. Natl. Acad. Sci. U. S. A. 100 (2003) 14211-14216
31. Campion J., et al. Inhibition by aldosterone of insulin receptor mRNA levels and insulin binding in U-937 human promonocytic cells. J. Steroid Biochem. Mol. Biol. 70 (1999) 211-218
32. Campion J., et al. Aldosterone impairs insulin responsiveness in U-937 human promonocytic cells via the downregulation of its own receptor. Cell Biochem. Funct. 20 (2002) 237-245
33. Carranza M.C., et al. Decreased insulin receptor number and affinity in subcutaneous adipose tissue in a patient with primary hyperaldosteronism. Rev. Clin. Esp. 188 (1991) 414-417
34. Fallo F., et al. Prevalence and characteristics of the metabolic syndrome in primary aldosteronism. J. Clin. Endocrinol. Metab. 91 (2006) 454-459
35. Giacchetti G., et al. Aldosterone as a key mediator of the cardiometabolic syndrome in primary aldosteronism: an observational study. J. Hypertens. 25 (2007) 177-186
36. Strazzullo P., et al. Genetic variation in the renin-angiotensin system and abdominal adiposity in men: the Olivetti Heart Study. Ann. Intern. Med. 138 (2003) 17-23
37. Engeli S., and Sharma A.M. The renin-angiotensin system and natriuretic peptides in obesity-associated hypertension. J. Mol. Med. 79 (2001) 21-29
38. Vaz M., et al. Regional sympathetic nervous activity and oxygen consumption in obese normotensive human subjects. Circulation 96 (1997) 3423-3429
39. Haynes W.G., et al. Receptor-mediated regional sympathetic nerve activation by leptin. J. Clin. Invest. 100 (1997) 270-278
40. Goodfriend T.L., et al. Epoxy-keto derivative of linoleic acid stimulates aldosterone secretion. Hypertension 43 (2004) 358-363
41. Krug, A.W. et al. Human adipocytes induce an ERK1/2 MAP kinase-mediated upregulation of steroidogenic acute regulatory protein (StAR) and an angiotensin II-sensitization in human adrenocortical cells. Int. J. Obes. 31, 1605-1616
42. Nagase M., et al. Enhanced aldosterone signaling in the early nephropathy of rats with metabolic syndrome: possible contribution of fat-derived factors. J. Am. Soc. Nephrol. 17 (2006) 3438-3446
43. Ross S.E., et al. Inhibition of adipogenesis by Wnt signaling. Science 289 (2000) 950-953
44. Longo K.A., et al. Wnt signaling protects 3T3-L1 preadipocytes from apoptosis through induction of insulin-like growth factors. J. Biol. Chem. 277 (2002) 38239-38244
45. Gordon M.D., and Nusse R. Wnt signaling: multiple pathways, multiple receptors, and multiple transcription factors. J. Biol. Chem. 281 (2006) 22429-22433
46. Molenaar M., et al. XTcf-3 transcription factor mediates β-catenin-induced axis formation in Xenopus embryos. Cell 86 (1996) 391-399
47. Schinner S., et al. Adipocyte-derived products induce the transcription of the StAR promoter and stimulate aldosterone and cortisol secretion from adrenocortical cells through the Wnt-signaling pathway. Int. J. Obes. (Lond.) 31 (2007) 864-870